Legend Biotech is trying to turn early success in a blood cancer treatment into broader use, helped by easier rules for clinics and a push into more countries. The big question is whether it can scale manufacturing and keep its edge while rivals and even partners bring out alternative therapies.Read more
Legend Biotech’s leading cell therapy for multiple myeloma is seeing fast real-world adoption, supported by encouraging long-term patient outcomes and easier treatment in outpatient settings. The big question is whether new factory capacity, overseas launches, and a broader next wave of treatments can keep growth going even as rivals catch up and pricing comes under pressure.Read more
Legend Biotech rides growing demand for cancer cell treatments, but tighter price controls and tougher reimbursement rules could squeeze what it can charge and slow growth. With so much depending on one lead therapy, rivals with easier-to-deliver alternatives could quickly change the outlook.Read more
No trending discussion available.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
